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Abstract
Background: Adherence to prescribed medications is a key dimension of healthcare quality. The aim of this large
population-based study was to evaluate self-reported medication adherence and to identify factors linked with poor
adherence in patients with type 2 diabetes in France.
Methodology: The ENTRED study 2007, a French national survey of people treated for diabetes, was based on a
representative sample of patients who claimed reimbursement for oral hypoglycaemic agents and/or insulin at least three
times between August 2006 and July 2007, and who were randomly selected from the database of the two main National
Health Insurance Systems. Medication adherence was determined using a six-item self-administered questionnaire. A
multinomial polychotomous logistic regression model was used to identify factors associated with medication adherence in
the 3,637 persons with type 2 diabetes.
Principal Findings: Thirty nine percent of patients reported good medication adherence, 49% medium adherence and 12%
poor adherence. The factors significantly associated with poor adherence in multivariate analysis were socio-demographic
factors: age ,45 years, non-European geographical origin, financial difficulties and being professionally active; disease and
therapy-related factors: HbA1c.8% and existing diabetes complications; and health care-related factors: difficulties for
taking medication alone, decision making by the patient only, poor acceptability of medical recommendations, lack of
family or social support, need for information on treatment, reporting no confidence in the future, need for medical support
and follow-up by a specialist physician.
Conclusions: In a country with a high level of access to healthcare, our study demonstrated a substantial low level of
medication adherence in type 2 diabetic patients. Better identification of those with poor adherence and individualised
suitable recommendations remain essential for better healthcare management.
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Introduction
Diabetes mellitus, a complex chronic disease, is a growing
worldwide epidemic with the number of people with diabetes
estimated to reach 330 million by 2030 [1]. Given the high
morbidity and mortality associated with the disease, primarily due
to macrovascular complications, type 2 diabetes is a major public-
health concern. Most European countries have formulated
evidence-based guidelines with clear targets [2,3], but actual care
often falls far short of these targets [4,5].
A key dimension of healthcare quality is adherence to
prescribed medications. According to the World Health Organi-
zation (WHO), adherence is the extent to which a person’s
behaviour – taking medication, following a diet, and/or executing
lifestyle changes – corresponds with agreed recommendations
from the health care provider [6]. However, medication non-
adherence is particularly common among patients with type 2
diabetes [7] and inadequate adherence compromises safety and
treatment effectiveness, leading to increased mortality and
morbidity with considerable direct and indirect costs to the
healthcare system [8,9]. A recent WHO report states that, because
the magnitude of non-adherence and the scope of its sequelae are
so alarming, more health benefits worldwide would result from
improving adherence to existing treatments than by developing
new medical treatments [6].
Previously, numerous studies have explored potential risk
factors of adherence to medicines across a variety of conditions.
However, the majority of studies have explored largely unmodifi-
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used to measure adherence. Frequently cited risk factors include
age, sex, ethnicity, income, education, and comorbidity though
their relationship to adherence has been inconsistent due to
variations in study designs and sample populations [7,10–12].
Therefore there is a continuing need to better identify factors
related to medication adherence. Moreover, previous studies on
medication adherence often included a limited number of diabetic
patients and with selected patient population [13–27], which
limited the generalizability of the results. This large population
based study, the largest European study to our knowledge, was
conducted to evaluate medication adherence in people with type 2
diabetes, and to identify the risk factors for poor adherence and
especially, modifiable factors.
Methods
Ethics Statement
The French National Ethics Committee and the French Data
Protection Authority Committee gave its approval to the
ENTRED study. According to the French regulations, written
consent for filling questionnaire was not required as no
intervention was performed on the participants and no blood or
human tissue was considered. Filling a self-reported questionnaire
and mailing it back was thus considered as consent for all
participants. For medical data filled by medical practitioners,
participants who provided addresses of their care practitioners
filled a form which was sent to the care practitioners to authorize
them to provide further medical information.
Study population and design
The ENTRED study was a French national public survey. A
complex random sample was selected from all patients aged over
18 years who claimed reimbursement for oral hypoglycaemic
agents (OHA) and/or insulin at least three times between August
2006 and July 2007, from the two main National Health Insurance
Systems (NHIS), which cover all active and retired employees and
their relatives—about 80% of the French population. To classify
the different types of diabetes, we used an epidemiological
algorithm: people diagnosed before the age of 45 years and
treated with insulin within two years from diagnosis were classified
as having type 1 diabetes and have not been considered for this
study.
A detailed questionnaire with a total of 110 questions was sent
to all patients (48% response rate; n=3,973 with 3,637 type
2 diabetic patients) and a medical questionnaire was also sent to
the medical-care providers of those among the responders who
gave their medical provider’s addresses (63% response rate;
n=2,485). Care providers reported the most recent clinical
measurements.
Medication adherence, the dependant variable, was analysed in
the subgroup of people with type 2 diabetes. The independent
variables to explain the medication adherence included socio-
demographic characteristics (age, gender, education level, geo-
graphical origin, marital status, residence, professional activity,
financial level, complementary health insurance…), characteristics
associated with disease and therapy (time since diabetes diagnosis,
type of treatment, body mass index, hypertension, dyslipidaemia,
smoking state, glycaemic control, microvascular or macrovascular
complications…), and associated with medical care (decision
making, follow-up by a specialist, acceptability of medical
recommendations, ability for taking medicine alone, need for
medical support or information on treatment…).
Measure of medication adherence
In this study, medication adherence (referring to any medicine,
not just for diabetes) was determined using a six item self-
administered questionnaire, drawing upon the works by Girerd et
al. [28]. Patients responded yes or no to each of the following
questions: (1) do you sometimes forget to take your medicine, (2)
have you ever run out of your medicine, (3) do you sometimes take
your medicine late, (4) do you sometimes decide not to take your
medicine because someday you feel that your treatment do more
harm than good, (5) do you think that you have too many pills to
take, (6) when you feel better, do you sometimes stop taking your
medicine. It has been shown that such a questionnaire has
sufficient validity and reliability [28]. Compared to a clinical
evaluation of medication adherence, the values of kappa indices
were 0.65 in ‘‘good adherence’’ when ‘‘No’’ was answered to the 6
items, 0.5 in ‘‘medium adherence’’ when 1 or 2 ‘‘Yes’’ were given
and 0.56 in ‘‘poor adherence’’ when 3 or more ‘‘Yes’’ were given
[28].
Statistical analyses
Descriptive analyses were first performed. In data reported by
patients, missing data for medication adherence were excluded
from analyses. To minimise potential non-response biases, all
analyses were weighted to take into account the participation rate
based on socio-demographic data and the type of antidiabetic
treatment. Quantitative values are expressed as means 6 standard
deviation, and were compared by Student’s t test, analysis of
variance or nonparametric test when appropriate, while qualita-
tive values were compared by the x
2 test or Fisher’s exact test. The
outcome of interest, medication adherence, was classified into
three categories; ‘good’, ‘medium’ and ‘poor’ and was treated as a
nominal variable since the proportional odds assumption was
rejected. A multinomial polychotomous logistic regression model
was used to estimate the effect of each covariate on the odds of
poor adherence and on the odds of medium adherence versus
good adherence, while simultaneously adjusting for all other
variables in the model. All statistical analyses took into account the
sample survey design and were carried out using SAS version 9.1.3
(SAS Institute Inc, Cary, NC). The characteristics of those who
responded to the detailed questionnaire were compared with those
who did not, using the 2007 administrative data available for all
people.
Results
Participants’ characteristics
This study included a total of 3,637 type 2 diabetic patients
(2,138 men and 1,499 women) with a mean age of 65 years (18 to
102 years). The main socio-demographic and clinical baseline
characteristics of the responders are summarized in Table 1.
Eighty one percent were treated with OHA without insulin, mean
HbA1c was 7.0% and 41% had microvascular or macrovascular
complications. Respondents to the survey were slightly younger
than non-respondents (64 years versus 66 years on average;
p,0.0001), most frequently male (59% versus 52%; p,0.0001),
most frequently born in France (79% versus 70%; p,0.0001), less
likely to be treated with OHA without insulin (74% versus 78%;
p,0.0001) and had better medical follow-up (43% versus 35%
had three HbA1c tests per year; p,0.0001).
Medication adherence
Thirty nine percent of patients had good adherence, 49%
medium adherence and 12% poor adherence: 18% of patients
reported sometimes forgetting to take their medicine, 9% running
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4% sometimes deciding not to take their medicine because
someday they felt that their treatment do more harm than good,
34% having too many pills to take and 5% sometimes stopping to
take their medicine when they felt better.
In univariate analysis, many factors were associated with
medication adherence (not detailed). On the contrary gender
and duration since diagnosis did not affect medication adherence
(p=0.93 and 0.90, respectively). Patients with professional activity
(who currently work) forgot more often to take their medicine
(30% versus 15%, p,0.0001) and took more often their medicine
late (51% versus 35%, p,0.0001).
In polychotomous logistic regression (Table 2), socio-demo-
graphic factors significantly associated with poor (versus good)
adherence were: age ,45 years (Odds Ratio (OR)=5.2), non-
European geographical origin (OR=2.6), financial difficulties
(OR=1.7) and being professionally active (OR=1.5). Disease and
therapy-related factors significantly associated with poor adher-
ence were: HbA1c.8% (OR=2.0) and existing diabetes compli-
cations (OR=1.7). A trend was observed with self-reported
hypertension (OR=1.4, p=0.08) and dyslipidemia (OR=1.4,
p=0.08) while being treated with insulin and diabetes duration
did not influence medication adherence. Lastly, health care-
related factors significantly associated with poor adherence were:
difficulties for taking medication alone (OR=3.8), decision
making by the patient only (OR=3.3), poor acceptability of
medical recommendations (OR=2.7), lack of family or social
support (OR=2.5), need for information on treatment (OR=2.0),
reporting no confidence in the future (OR=1.6), need for medical
support (OR=1.6) and follow-up by a specialist physician
(OR=1.4).
Discussion
Medication adherence is a key component of self-management
for patients with diabetes. Our population-based study found a low
rate of good adherence (39%), which means that for many
patients, medication adherence could be improved. One of the
most common challenges physicians face with a patient with
poorly controlled diabetes is to try to figure out if the patient’s
hyperglycemia is due to poor adherence or is occurring despite
proper medication use (i.e., therapy needs to be intensified).
Since patients may be more willing to report suboptimal
adherence (self-reports typically provide overestimates of adher-
ence for several reasons: first, they may rely on patients’ own
interpretation or memory of what advice was given and, if
accepted, how closely it has been followed; second, patients may
tend to report higher levels of adherence in order to please health
care providers or avoid embarrassment), probing the handful of
strongly predictive factors we have identified is useful for two
reasons. First, it can help identify those likely to be poor adherers.
Second, it can direct the physician on aspects of diabetes and its
management on which they should focus their patient education
efforts [29].
Our results are consistent with previous studies and particularly,
with the DARTS study which found that adequate adherence
(adherence index $90%) was found in only approximately one in
three of those with type 2 diabetes receiving OHA [16].
Nonetheless, a recent meta-analysis found that medication
adherence ranged from 36% to 93% depending on the defini-
tion applied [7]. However, the lack of standard measurements
prevents comparison being made between studies and across
populations. We also found that poor glycaemia control and
presence of microvascular or macrovascular complications
were more common among patients with poor adherence to
medications.
In previous studies, many factors were inconsistently found as
risk factors of poor adherence to drug therapy in type 2 diabetes.
The statistical power of this study based on a large sample size was
sufficient to detect small differences. Age [16,30], financial
difficulties [6], ethnicity [23,24], psychological factors [31], social
support [6], quality of the relationship between patient and
physician [32] were confirmed as risk factors of medication
adherence. In this study, we particularly focused on modifiable
Table 1. Main socio-demographic and clinical baseline
characteristics of the 3,637 responders, Entred study.
Variables Study sample
Age [SD] 65.0 [11.1]
Sex - n (%)
male 2138 (54.4)
female 1499 (45.6)
Geographical origin - n (%)
France 2694 (79.0)
Europe (except France) 373 (11.2)
other 346 (9.8)
Education level - n (%)
low 529 (16.3)
medium 2177 (63.9)
high 769 (19.8)
Marital status - n (%)
unmarried 1105 (32.8)
married 2491 (67.2)
Complementary health insurance - n (%)
yes 3157 (88.0)
no 432 (12.0)
Financial difficulties - n (%)
no 1668 (46.5)
few 1095 (31.8)
yes 762 (21.7)
Professional activity - n (%)
yes 2929 (83.0)
no 672 (17.0)
Treatment - n (%)
OHA 2859 (80.5)
insulin +/2 OHA 742 (19.5)
Body mass index - n (%)
,25 kg/m2 650 (19.0)
25–29 kg/m2 1405 (39.4)
$30 kg/m2 1446 (41.6)
Smoking - n (%)
yes 659 (17.4)
no 2950 (82.6)
Presence of complication - n (%)
yes 1405 (41.4)
no 2014 (58.6)
SD: standard deviation; OHA: oral hypoglycaemic agents.
doi:10.1371/journal.pone.0032412.t001
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Good
adherence
Medium versus good
adherence Poor versus good adherence
Variables Subcategory P-value N N OR 95% CI N OR 95% CI
Socio-demographic factors
Age (years) 18–44 ,0.0001 23 50 1.8 1.1–3.1 38 5.2 2.7–10.1
45–64 522 888 1.5 1.2–1.8 236 1.8 1.3–2.4
65–84 808 815 1 147 1
85 and more 63 37 0.5 0.3–0.8 10 1.0 0.5–2.0
Geographical origin France ,0.0001 1,085 1,340 1 269 1
Europe* 138 182 1.0 0.8–1.3 53 1.3 0.9–1.9
other 87 172 1.3 1.0–1.8 87 2.6 1.8–3.9
Complementary health insurance no 0.12 167 192 1 79 1
yes 1,229 1,581 1.3 1.0–1.6 347 0.9 0.6–1.3
Financial difficulties no 0.02 739 780 1 149 1
few 417 559 1.2 1.0–1.4 119 1.1 0.8–1.5
yes 203 408 1.4 1.1–1.7 151 1.7 1.2–2.4
Professional activity no 0.04 1,199 1,423 1 307 1
yes 200 356 1.2 0.9–1.5 116 1.5 1.1–2.1
Disease and therapy-related factors
Treatment OHA 0.15 1,158 1,377 1 324 1
insulin +/2 OHA 248 393 1.1 0.9–1.3 101 0.9 0.6–1.2
Glycated haemoglobin #6.5% 0.01 235 234 1 36 1 1
6.5–8% 260 355 1.4 1.1–1.8 65 1.7 1.1–2.7
.8% 66 105 1.4 1.1–1.7 31 2.0 1.3–3.0
Presence of microvascular or
macrovascular complications
no 0.0009 834 970 1 210 1
yes 487 723 1.3 1.1–1.6 195 1.7 1.3–2.2
Hypertension no 0.08 580 623 1 144 1
yes 778 1,099 1.2 1.0–1.4 269 1.4 1.0–1.8
Dyslipidemia no 0.08 627 690 1 144 1
yes 700 1,014 1.1 1.0–1.3 267 1.4 1.1–1.8
Health care-related factors
Difficulties for taking medicine alone no 0.0002 1,326 1,660 1 373 1
yes 28 80 1.8 1.1–2.8 41 3.8 2.2–6.9
Decision making physician and
patient
,0.0001 854 909 1 191 1
physician 411 637 1.4 1.1–1.6 146 1.5 1.2–2.0
patient 73 168 1.9 1.4–2.6 63 3.3 2.1–5.0
Acceptability of medical
recommendations
good 0.004 1,174 1,440 1 307 1
poor 30 123 2.1 1.4–3.3 56 2.7 1.6–4.6
Family or social support yes 0.0002 1,064 1,302 1 271 1
no 88 224 1.4 1.0–1.9 102 2.5 1.7–3.6
Need for information on treatment no ,0.0001 1,162 1,368 1 303 1
yes 137 327 1.7 1.3–2.1 106 2.0 1.4–2.7
Confidence in the future yes 0.0009 1,040 1,091 1 199 1
no 275 613 1.5 1.2–1.8 203 1.6 1.2–2.2
Need for medical support no 0.002 1,045 1,122 1 214 1
yes 371 668 1.2 1.0–1.5 217 1.6 1.2–2.1
Follow-up by a specialist no 0.005 1,271 1,560 1 352 1
yes 145 230 1.1 0.9–1.4 79 1.4 1.2–2.5
*Except France; OR: odds ratio; 95% CI: 95% confidence interval; OHA: oral hypoglycaemic agents.
doi:10.1371/journal.pone.0032412.t002
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ity of medical recommendations, medical support …). Contrary to
Lawton et al. who found that non-adherence was related more to
patient forgetfulness than to specific concerns about medications
or interaction with physicians [33], our results show the
importance of shared decision-making in which the beliefs and
preferences of the patient are taken into consideration. This
patient centred approach should enhance adherence and
improve outcomes [34,35]. Other interesting risk factors of poor
adherence found in this study were the presence of difficulties for
taking medicine alone, need for information and poor acceptabil-
ity of medical recommendations. These two last findings confirm
the need to better inform patients about their disease and
treatment and to individually adapt recommendations. This could
underline the insufficiency of patient education especially since
it is now well established that education enables the patient to
acquire knowledge and understanding of diabetes, self-
management skills and psychosocial competencies [36,37]. Social
or family support is also crucial. Family members are frequently
involved and recognized as supportive: they act as counsellors
encouraging diet and exercise behaviours, facilitating adherence
with medication, and altogether helping patients to ‘‘live with the
disease’’ [38]. Lastly, the fact that professional activity was
associated with poor adherence could be surprising considering
a potential healthy worker effect. However, we clearly report that
active patients more often forget to take their medicine and/or
take their medicine late, and the relationship remains significant
after adjustments.
Ultimately, two categories of risk factors for poor adherence
could be distinguished: unmodifiable factors (such as age,
ethnicity…) or factors that are hardly modifiable in the context
of the medical relationship (financial difficulties, presence of
professional activity…) which may help physicians to better
identify patients at high risk for poor adherence and to adapt
their medical care ; and some modifiable factors (such as social
support, quality of the relationship between patient and physician,
need for information, poor acceptability of medical recommenda-
tions…) on which physicians could focus their efforts to improve
medication adherence and, as a consequence, to improve
glycaemia control. In our study, no significant difference in
adherence was found between males and females, which has
already been shown [16]. However, it should be noted that the
DIABASIS study evidenced clear gender differences in the
perception and self-management of disease. Women took the
disease more seriously, reported a higher impact on daily life and
were more involved in self-management, while men relied more
on family support. The authors suggested that physicians should
take these differences in attitudes into account when counseling,
educating and treating patients [38].
After identifying patients at high risk for poor adherence, the
physician should try more than usual to apply multiple
interventions in order to improve adherence: educational,
behavioral, and affective interventions [39]. Educational interven-
tions seek to improve adherence by providing information and/or
skills. Education may take the form of individual instruction or
group classes. In any event, a key element of successful educational
strategies is providing simple, clear messages, hopefully tailored to
the needs of the individual, and verifying that the messages have
been understood. Behavioral approaches have their roots in
cognitive-behavioral psychology and use techniques such as
reminders, memory aids, synchronizing therapeutic activities with
routine life events (e.g., taking pills before you shower), goal-
setting, self-monitoring, contracting, skill-building, and rewards.
For example, reminders may be mailed, e-mailed, or telephoned.
What is important is that the behavior in question has been
negotiated with and accepted by individual patients so that
adoption of the behavior has a chance of succeeding in the long
term. Affective interventions seek to enhance adherence by
providing emotional support and encouragement. Finally, it
should be remembered that application of multiple interventions
of different types is more effective than any single intervention
[39].
Our results should be viewed with consideration of several
limitations. One limitation was the use of self-report data on
medication adherence, because of a resulting tendency to
overestimate adherence due to recall biases and social desirability.
However, self-reported questionnaires have frequently been used
because they are low in both cost and time expenditure and
appropriate for large population-based samples. Subsequent
research suggests that the self-report methods provide a reasonably
accurate estimate of adherence [40]. Besides, our results based on
self-report questionnaires were consistent with the literature, poor
glycaemic control being more common among patients with low
adherence to medications [41,42] and many well-known factors
associated with poor adherence were also identified by our study.
The total number of medications prescribed to the patient has not
been assessed in our study. However, this factor has been
recognized as a contributor of patient adherence for a long time
[43] and does not need any more to be established. Biases linked to
participation are a common limitation, although our response rate
was in keeping with population-based surveys. It is possible that
respondents were more concerned about their diabetes than the
others and, as a result, this may have led to an overestimation of
medication adherence. To account for potential non response
biases, we weighted our results according to the participation rate,
based on socio-demographic data and type of antidiabetic
treatment, as these auxiliary variables were correlated with both
the non-response process and the survey estimate [44,45]. Lastly,
our study was cross sectional, where causal relationship between
the independent and dependent variables cannot be fully
established.
Despite these limitations, this study provides valuable informa-
tion in support of the literature and has several major strengths.
The number of people with type 2 diabetes was large, and to our
knowledge larger than any European previously published study of
adherence. The studied sample constituted a large nationally
representative cohort of diabetic patients. Therefore, the gener-
alizability of the results to countries with similar health care system
is high. This study, combining multiple data sources (self-reported,
medical-care providers, data from the two main National Health
Insurance Systems), provided a large number of diabetes-related
variables.
In summary, medication adherence is vital for effective diabetes
management. Our findings point towards the interest of fine-
tuning the primary care provider’s approach to the individual
patient by taking into account medication adherence. More
evidence to support specific interventions that will be effective in
overcoming adherence challenges for diabetes patients is needed.
The patients should have a pivotal role in their diabetes
management. Therefore, they need to acquire knowledge and
skills, but also the ability for behavioural change, which often
requires intensive patient-centred health education. In a country
with a high level of access to healthcare, our study demonstrated a
low level of medication adherence. Better identification of patients
with poor adherence, who require a more specific and rigorous
patient physician relationship and individualised suitable recom-
mendations, remains essential to obtain better outcomes in type 2
diabetic patients.
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